-
Trial in Progress: A Phase 1 Study of Revumenib + Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia Harboring Genetic Alterations in KMT2A, NPM1, or NUP98 (SNDX-5613-0708)
-
Menin inhibition as a new therapeutic option for the Myeloproliferative Neoplasms
-
Co-targeting Menin and RAS in KMT2A-r/NPM1c AML with Activated RTK/RAS/MAPK Signaling
-
A Multicenter Phase 1 Trial Evaluating the Safety and Preliminary Efficacy of Revumenib as Post-Transplant Maintenance After Allogeneic Hematopoietic Cell Transplant in Patients with KMT2A-Rearranged or NPM1-Mutated Acute Leukemia
-
A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed NPM1-mutated acute myeloid leukemia (REVEAL-ND NPM1): Trial in progress
-
Revumenib + venetoclax/azacitidine in adults with newly diagnosed NPM1m or KMT2Ar acute leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002): Trial in progress